A phase I/II trial of a tetravalent live attenuated dengue vaccine in flavivirus antibody naive children

Trial Profile

A phase I/II trial of a tetravalent live attenuated dengue vaccine in flavivirus antibody naive children

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2010

At a glance

  • Drugs TDENV LAV (Primary)
  • Indications Dengue
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 30 Mar 2010 Additional lead trial centre identified as United States Medical Materiel Development Activity as reported by ClinicalTrials.gov.
    • 14 Feb 2008 The expected completion date for this trial is now 1 May 2004.
    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top